Related Post

Recently in Venture Capital

Recent Comments

• The Nursing Shortage: Part II - The Dialogue Continues
• Contemporary Psychology: Psychological Treatment in a Hospital Setting
• Consumers For Health Care Choices: Garrison Bliss, MD, Pioneer in Medical Practice
• Fighting De-Nursification
• Genentech’s Two Headed Monster: Lucentis and Avastin
• Nurses Wanted… Autoworkers Could Do
• Genentech’s Two Headed Monster: Lucentis and Avastin
• Reporting AIDS: HIV Vaccine Trials

The Changing Landscape of the Biotech Pharma Deal

 
Biotech and Pharma industry experts converse on deal making trends. Learn how you can position your technology and/or company for success in the current environment.

A seasoned panel discusses the evolution of deal models in the life science industry from the 1980s to present day. Panelists touch upon issues relating to the size of the deals, valuations, early stage /late stage deals, and recent acquisition activity (Takeda/Millennium; AstraZeneca/MedImmune; Imclone/Lilly). A must watch for anyone interested in Biotech Pharma deal making.

Moderator
- Ed Saltzman, President, DefinedHealth

Panelists
- Tamar D. Howson, MS, MBA, JSB Partners
- Dr. Christine T. Fischette, President, Enzo Therapeutics, Inc.
- Mark J. Simon, President, Williver Group